San Francisco startup Composition Therapeutics can be working on an oral, once-day-to-day GLP-1 drug known as GSBR-1290—the drug surpassed Wall Street’s expectations in June every time a mid-stage review showed common weight loss of around six% and it designs to start A different mid-stage demo to the tip of the yr—that founder and CEO Raymon